These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 23509826)
1. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Benteyn D; Van Nuffel AM; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A Biomed Res Int; 2013; 2013():976383. PubMed ID: 23509826 [TBL] [Abstract][Full Text] [Related]
2. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500 [TBL] [Abstract][Full Text] [Related]
3. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Wilgenhof S; Van Nuffel AMT; Benteyn D; Corthals J; Aerts C; Heirman C; Van Riet I; Bonehill A; Thielemans K; Neyns B Ann Oncol; 2013 Oct; 24(10):2686-2693. PubMed ID: 23904461 [TBL] [Abstract][Full Text] [Related]
4. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Jansen Y; Kruse V; Corthals J; Schats K; van Dam PJ; Seremet T; Heirman C; Brochez L; Kockx M; Thielemans K; Neyns B Cancer Immunol Immunother; 2020 Dec; 69(12):2589-2598. PubMed ID: 32591862 [TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680 [TBL] [Abstract][Full Text] [Related]
6. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
8. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017 [TBL] [Abstract][Full Text] [Related]
9. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076 [TBL] [Abstract][Full Text] [Related]
10. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987 [TBL] [Abstract][Full Text] [Related]
11. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140 [TBL] [Abstract][Full Text] [Related]
13. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Van Nuffel AM; Benteyn D; Wilgenhof S; Pierret L; Corthals J; Heirman C; van der Bruggen P; Coulie PG; Neyns B; Thielemans K; Bonehill A Mol Ther; 2012 May; 20(5):1063-74. PubMed ID: 22371843 [TBL] [Abstract][Full Text] [Related]
14. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Schuurhuis DH; Verdijk P; Schreibelt G; Aarntzen EH; Scharenborg N; de Boer A; van de Rakt MW; Kerkhoff M; Gerritsen MJ; Eijckeler F; Bonenkamp JJ; Blokx W; van Krieken JH; Boerman OC; Oyen WJ; Punt CJ; Figdor CG; Adema GJ; de Vries IJ Cancer Res; 2009 Apr; 69(7):2927-34. PubMed ID: 19318559 [TBL] [Abstract][Full Text] [Related]
15. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592 [TBL] [Abstract][Full Text] [Related]
16. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399 [TBL] [Abstract][Full Text] [Related]
17. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Wang QT; Nie Y; Sun SN; Lin T; Han RJ; Jiang J; Li Z; Li JQ; Xiao YP; Fan YY; Yuan XH; Zhang H; Zhao BB; Zeng M; Li SY; Liao HX; Zhang J; He YW Cancer Immunol Immunother; 2020 Jul; 69(7):1375-1387. PubMed ID: 32078016 [TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Wilgenhof S; Corthals J; Van Nuffel AM; Benteyn D; Heirman C; Bonehill A; Thielemans K; Neyns B Cancer Immunol Immunother; 2015 Mar; 64(3):381-8. PubMed ID: 25548092 [TBL] [Abstract][Full Text] [Related]
19. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Van Nuffel AM; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A Cancer Immunol Immunother; 2012 Jul; 61(7):1033-43. PubMed ID: 22159452 [TBL] [Abstract][Full Text] [Related]